China-based InventisBio (Shanghai) has signed a 'Collaboration Agreement' with China-based Betta Pharma, it was reported on Friday.
According to the contract, InventisBio will out-license D-0316's right in China (including mainland China, Hong Kong and Taiwan) to Betta Pharma and is to co-develop this drug in China. Betta Pharma will have the exclusive commercialisation rights for the D-0316 product in the country.
The product is a third-generation EGFR-T790M tyrosine kinase inhibitor discovered and developed independently by InventisBio. It is mainly utilised for the treatment of EGFR-mutant non-small cell lung cancer. The drug is presently in phase one clinical trial in China. Betta Pharma will pay upfront and R&D milestones to InventisBio worth RMB230m. After the product is marketed commercially, Betta Pharma will pay various sales milestones and tiered royalties based on annual sales.
IDEAYA Biosciences submits IND for IDE892; Targets Phase 1 in 4Q 2025
Airiver medical receives FDA approval for central airway stenosis trial
INOVIO to begin rolling submission of BLA for INO-3107
Calluna Pharma begins Phase 2 study of CAL101 in idiopathic pulmonary fibrosis
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Innovent Biologics receives approval over squamous cell lung cancer study
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
HUTCHMED completes enrollment in Phase III SANOVO trial of ORPATHYS and TAGRISSO in China
LivaNova announces commercial launch of Essenz Perfusion System in China
Precigen's PAPZIMEOS granted US FDA approval to treat with recurrent respiratory papillomatosis
Leads Biolabs completes patient enrollment in pivotal Opamtistomig trial for EP-NEC
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation